Technical Analysis for BLTE - Belite Bio, Inc.

Grade Last Price % Change Price Change
B 13.8 0.00% 0.00
BLTE closed unchanged on Monday, May 16, 2022, on 5 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Gapped Up Strength 0.00%
Gapped Up Strength 0.00%
Hot IPO Pullback Bullish Swing Setup 1.17%
Inside Day Range Contraction 1.17%
Gapped Down Weakness 1.17%
Hot IPO Pullback Bullish Swing Setup 2.22%
Down 3 Days in a Row Weakness 2.22%
Gapped Down Weakness 2.22%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 7 hours ago
Possible Inside Day about 7 hours ago
Down 2 % about 8 hours ago
Down 1% about 10 hours ago
60 Minute Opening Range Breakdown about 10 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Belite Bio, Inc. Description

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.


Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Diabetes Drug Development Steatohepatitis Hepatitis Non Alcoholic Fatty Liver Disease Liver Disease Oral Therapy

Is BLTE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 17.5
52 Week Low 8.8
Average Volume 1,140,385
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 14.04
Average True Range 0.00
RSI 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.04
MACD Signal Line 0.01
MACD Histogram 0.0296
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.67
Resistance 3 (R3) 14.66 14.36 14.53
Resistance 2 (R2) 14.36 14.14 14.37 14.48
Resistance 1 (R1) 14.08 14.00 13.93 14.09 14.43
Pivot Point 13.78 13.78 13.71 13.79 13.78
Support 1 (S1) 13.50 13.56 13.35 13.51 13.17
Support 2 (S2) 13.20 13.42 13.20 13.12
Support 3 (S3) 12.92 13.20 13.07
Support 4 (S4) 12.93